Kangpu Biopharmaceuticals, a China-based clinical-stage company, announced on Sunday that it has dosed its first patient in the United States Phase IIa clinical trial of KPG-818, an orally bioavailable NeoMIDESTM molecular glue, intended to treat systemic lupus erythematosus (SLE).
The Phase IIa trial, a multicentre, randomised, double-blind, placebo-controlled clinical study, is intended to assess the safety and tolerability, pharmacokinetics, and preliminary efficacy of KPG-818 in patients with SLE.
The product is a novel cereblon E3 ubiquitin ligase complex (CRL4-CRBN) modulator, produced by the company for the treatment of autoimmune diseases and hematologic malignancies. During a Phase Ib clinical study in SLE recently completed in the United States, the company stated that KPG-818 showcased good tolerability, a favourable pharmacokinetic profile, and substantial potency for the degradation of Ikaros and Aiolos (IKZF1 and IKZF3).
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca